A multicentre, open-label, phase III randomized trial supports the use of adjuvant gemcitabine in patients with advanced pancreatic cancer who undergo resection with curative intent. The median follow-up time for the 354 (of 368) patients included in the intention-to-treat analysis was 136 months. Compared with observation alone, adjuvant gemcitabine given for 6 months prolonged median disease-free survival and overall survival (measured at 5 and 10 years).